• +971 0000 000 000
  • info@verticaljournal.top

ViaDerma Update on Stability Testing, Global Sales Distribution, National Licensing, Nupelo & More

Grand News Network | October 24, 2023

LOS ANGELES, Calif., Oct. 24, 2023 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC:VDRM) is pleased to announce several new and exciting business updates for current and prospective shareholders, customers, partners, and healthcare providers.

The company is currently in the final phases of completing our stability testing requirements with our third-party testing facility. Based on the feedback we received from our testing partner last week, the company is on pace to have everything finalized by the end of October. The stability testing requirements are a crucial step in order to greenlight the approvals to distribute our lead product Vitastem Ultra throughout multiple countries in the Caribbean and Middle East, along with India - the largest populated nation on Earth with 1.486 billion people, which recently surpassed China earlier this year.

ViaDerma's management team has been working diligently with our new contract manufacturer to ramp up production capabilities in order to accommodate several large volume orders of 250,000 to 300,000 plus units per country this year. ViaDerma's Founder & CEO, Dr. Christopher Otiko is expected to travel to Egypt in Q4 to present Vitastem Ultra to their government officials as the company is expecting to fulfill purchase orders of 250,000 units or more in Egypt alone.

Upon the completion of stability testing for Vitastem Ultra, we will be able to begin distributing Vitastem internationally by fulfilling initial purchase orders throughout the Caribbean, Middle East, and India where the demand for Vitastem is highest. Based on the discussions with our sales partners, ViaDerma is planning to initially distribute 300,000 plus units per country yearly and expect to scale the volume of units ...

Full story available on Benzinga.com


Disclaimer: The views, recommendations, and opinions expressed in this content belong solely to the third-party experts. This site was not involved in the writing and production of this article.


Disclaimer Press Release Banner